The effect of giving influenza vaccination to general practitioners: a controlled trial [NCT00221676]

Barbara Michiels, Hilde Philips, Samuel Coenen, Fernande Yane, Toon Steinhauser, Sofie Stuyck, Joke Denekens, Paul Van Royen, Barbara Michiels, Hilde Philips, Samuel Coenen, Fernande Yane, Toon Steinhauser, Sofie Stuyck, Joke Denekens, Paul Van Royen

Abstract

Background: No efficacy studies of influenza vaccination given to GPs have yet been published. Therefore, our purpose was to assess the effect of an inactivated influenza vaccine given to GPs on the rate of clinical respiratory tract infections (RTIs) and proven influenza cases (influenza positive nose and throat swabs and a 4-fold titre rise), while adjusting for important covariates.

Methods: In a controlled trial during two consecutive winter periods (2002-2003 and 2003-2004) we compared (77 and 100) vaccinated with (45 and 40) unvaccinated GPs working in Flanders, Belgium. Influenza antibodies were measured immediately prior to and 3-5 weeks after vaccination, as well as after the influenza epidemic. During the influenza epidemic, GPs had to record their contact with influenza cases and their own RTI symptoms every day. If they became ill, the GPs had to take nose and throat swabs during the first 4 days. We performed a multivariate regression analysis for covariates using Generalized Estimating Equations.

Results: One half of the GPs (vaccinated or not) developed an RTI during the 2 influenza epidemics. During the two influenza periods, 8.6% of the vaccinated and 14.7% of the unvaccinated GPs had positive swabs for influenza (RR: 0.59; 95%CI: 0.28 - 1.24). Multivariate analysis revealed that influenza vaccination prevented RTIs and swab-positive influenza only among young GPs (ORadj: 0.35; 95%CI: 0.13 - 0.96 and 0.1; 0.01 - 0.75 respectively for 30-year-old GPs). Independent of vaccination, a low basic antibody titre against influenza (ORadj 0.57; 95%CI: 0.37 - 0.89) and the presence of influenza cases in the family (ORadj 9.24; 95%CI: 2.91 - 29) were highly predictive of an episode of swab-positive influenza.

Conclusion: Influenza vaccination was shown to protect against proven influenza among young GPs. GPs, vaccinated or not, who are very vulnerable to influenza are those who have a low basic immunity against influenza and, in particular, those who have family members who develop influenza.

Trial registration: ClinicalTrials.gov NCT00221676.

Figures

Figure 1
Figure 1
The incidence of influenza-like illnesses (ILI) and acute respiratory infections (ARI) recorded by sentinel physicians in Belgium.
Figure 2
Figure 2
Flowchart of GPs' missing diaries and serology data.
Figure 3
Figure 3
The effect of influenza vaccination (OR) on respiratory tract infections with influenza-positive nose and throat swabs for different ages: multivariate regression analysis.

References

    1. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and Control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2005;54:1–40.
    1. Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine. 2005;23:2251–2255. doi: 10.1016/j.vaccine.2005.01.043.
    1. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults (Cochrane review) Cochrane Database Syst Rev. 2005;2
    1. Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Murray GD, Stott DJ. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 2000;355:93–97. doi: 10.1016/S0140-6736(99)05190-9.
    1. Potter J, Stott DJ, Roberts MA. Influenza Vaccination of Health Care Workers in Long-Term- Care Hospitals Reduces the Mortality of Elderly Patients. J Infect Diseases. 1997;175:1–6.
    1. Michiels B, Coenen S, Avonts D, Van Royen P, Denekens J. Who benefits from an influenza vaccination of GPs? Vaccine. 2001;20:1–2. doi: 10.1016/S0264-410X(01)00255-9.
    1. Elder AG, O'Donnell B, McCruden EAB, Symington IS, Carman WF. Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993–1994 epidemic: results of serum testing and questionnaire. BMJ. 1996;313:1241–1242.
    1. Betts RF, Treanor JJ. Approaches to improved influenza vaccination. Vaccine. 2000;18:1690–1695. doi: 10.1016/S0264-410X(99)00508-3.
    1. Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet. 1984;1:705–708. doi: 10.1016/S0140-6736(84)92222-0.
    1. Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine. 2004;22:2566–2577. doi: 10.1016/j.vaccine.2003.12.018.
    1. Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Human Vaccines. 2005;1:37–42.
    1. Kleinbaum DG, Klein M. Logistic Regression. New York: Springer-Verlag; 2002.
    1. European Influenza Surveillance Scheme . Annual report: 2002–2003 influenza season. NIVEL, Utrecht, the Netherlands; 2004.
    1. Yane F, Libotte ML, Brochier B. Surveillance van griep in België Seizoen 2003–2004. Scientific Institute of Public Health, National Influenza Centre, Brussels, België; 2004.
    1. Russell KL, Ryan MAK, Hawksworth A, Freed NE, Irvine M, Daum LT. Effectiveness of the 2003–2004 influenza vaccine among US military basic trainees: a year of suboptimal match between vaccine and circulating strain. Vaccine. 2005;23:1981–1985. doi: 10.1016/j.vaccine.2004.10.023.
    1. Michiels B, Philips H, Coenen S, Denekens J, Van Royen P. Serum antibodies against circulating influenza strains among vaccinated and unvaccinated general practitioners during two consecutive years (2002–2003) Vaccine. 2006;24:3145–3152. doi: 10.1016/j.vaccine.2006.01.040.
    1. Epidemic Observation Unit Retrospective survey of the 1957 epidemic of Asian influenza. Part II. J Coll Gen Pract. 1958;1:258–260.
    1. Ellis JS, Fleming DM, Zambon MC. Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J Clin Microbiol. 1997;35:2076–2082.
    1. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals. A randomized trial. JAMA. 1999;281:908–913. doi: 10.1001/jama.281.10.908.
    1. Monto AS, Ross HW. Acute respiratory illness in the community: effect of family composition, smoking and chronic symptoms. Br J Prev Soc Med. 1977;31:101–108.
    1. Harbarth S, Siegrist CA, Schira JC, Wunderli W, Pittet D. Influenza immunization: improving compliance of health care workers. Inf Control Hosp Epidemiol. 1998;19
    1. Palache AM, Beyer WEP, Lüchters G, Völker R, Sprenger MJW, Masurel N. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine. 1993;11:892–908. doi: 10.1016/0264-410X(93)90375-8.
    1. Stevenson PG, Doherty PC. Cell-mediated immune response to influenza virus. In: KG N, editor. Textbook of influenza. Oxford: Blackwell Science Ltd; 1998. pp. 278–287.
    1. Fox JP, Cooney MK, Hall CE, Foy Hm. Influenza virus infections in Seattle families, 1975–1979. Am J Epidemiol. 1982;116:228–242.
    1. Nguyen-Van-Tam JS. Epidemiology of Influenza. In: Nicholson KG, editor. Textbook of Influenza. Oxford: Blackwell Science Ltd; 1998. pp. 181–206.
    1. Jefferson T, Demicheli V, Deeks J, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults [Systematic Review] Cochrane Database of Systematic Reviews. 2005;3
    1. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden F, Sugaya N, Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759–765. doi: 10.1016/S0140-6736(04)16934-1.
    1. Edwards KM, Dupont WD, Westrich MK, Plummer WD, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for prevention of influenza A disease. J Infect Dis. 1994;169:68–76.
    1. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess KR. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997;15:1114–1122. doi: 10.1016/S0264-410X(97)00003-0.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren